Recent reports have verified PLVAP as a practical marker in addition to a prospective treatment targeting lung cancer [28], cholangiocarcinoma [19], colorectal cancer (CRC) [29], pancreatic adenocarcinoma [30], melanomas [31], liver cancer [32] and brain tumors [33, 34]. This evidence concerns the gene PLVAP and cholangiocarcinoma.